Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in Relapsed or Refractory Peripheral T-Cell Lymphoma
NCT03075553Phase 2Terminated
- Sponsor
- Mayo Clinic
- Start
- May 2017
- Primary completion
- May 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in peripheral T-cell lymphoma (PTCL), sponsored by Mayo Clinic. Started May 2017; status: terminated.
02
Drugs
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT03075553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03075553.